467 related articles for article (PubMed ID: 38570883)
1. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.
Shao W; Yao Y; Yang L; Li X; Ge T; Zheng Y; Zhu Q; Ge S; Gu X; Jia R; Song X; Zhuang A
Exp Hematol Oncol; 2024 Apr; 13(1):37. PubMed ID: 38570883
[TBL] [Abstract][Full Text] [Related]
2. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.
Baulu E; Gardet C; Chuvin N; Depil S
Sci Adv; 2023 Feb; 9(7):eadf3700. PubMed ID: 36791198
[TBL] [Abstract][Full Text] [Related]
3. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
Shafer P; Kelly LM; Hoyos V
Front Immunol; 2022; 13():835762. PubMed ID: 35309357
[TBL] [Abstract][Full Text] [Related]
4. Emerging Strategies in TCR-Engineered T Cells.
Wei F; Cheng XX; Xue JZ; Xue SA
Front Immunol; 2022; 13():850358. PubMed ID: 35432319
[TBL] [Abstract][Full Text] [Related]
5. Evolution of CD8
Sun Y; Li F; Sonnemann H; Jackson KR; Talukder AH; Katailiha AS; Lizee G
Cells; 2021 Sep; 10(9):. PubMed ID: 34572028
[TBL] [Abstract][Full Text] [Related]
6. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
7. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
8. The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.
Zhang J; Wang L
Technol Cancer Res Treat; 2019 Jan; 18():1533033819831068. PubMed ID: 30798772
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
10. [T cell receptor-based immunotherapy: a review].
Chen Y; Gao GF; Tan S
Sheng Wu Gong Cheng Xue Bao; 2023 Oct; 39(10):4004-4028. PubMed ID: 37877387
[TBL] [Abstract][Full Text] [Related]
11. TCR engineered T cells for solid tumor immunotherapy.
Zhang Y; Liu Z; Wei W; Li Y
Exp Hematol Oncol; 2022 Jun; 11(1):38. PubMed ID: 35725570
[TBL] [Abstract][Full Text] [Related]
12. Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia.
Campillo-Davo D; Anguille S; Lion E
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572745
[TBL] [Abstract][Full Text] [Related]
13. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges.
Pang Z; Lu MM; Zhang Y; Gao Y; Bai JJ; Gu JY; Xie L; Wu WZ
Biomark Res; 2023 Dec; 11(1):104. PubMed ID: 38037114
[TBL] [Abstract][Full Text] [Related]
14. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
15. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
16. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
[TBL] [Abstract][Full Text] [Related]
17. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy.
Yang D; Duan Z; Yuan P; Ding C; Dai X; Chen G; Wu D
Biochem Biophys Res Commun; 2023 Dec; 687():149209. PubMed ID: 37944471
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application.
Xu R; Du S; Zhu J; Meng F; Liu B
Cancer Lett; 2022 Oct; 546():215840. PubMed ID: 35921969
[TBL] [Abstract][Full Text] [Related]
19. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Chandran SS; Klebanoff CA
Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
[TBL] [Abstract][Full Text] [Related]
20. [Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors].
Ikeda H
Rinsho Ketsueki; 2019; 60(6):716-722. PubMed ID: 31281165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
